IJCS | Volume 32, Nº2, March/April 2019

156 1. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002; 287(10): 1308-20. 2. Arteaga E, Ianni BM, Fernandes F, Mady C. Benign outcome in a long- term follow-up of patients with hypertrophic cardiomyopathy in Brazil. Am Heart J. 2005;149(6):1099-105. 3. Marsiglia JDC, Batitucci MCP, Paula F, Barbirato C, Arteaga E, Araújo AQ. Estudo de mutações causadoras de cardiomiopatia hipertrófica em um grupo de pacientes no Espírito Santo, Brasil. Arq Bras Cardiol. 2010; 94(1):10-7. 4. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002; 287(10):1308-20. 5. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden death. J AmColl Cardiol. 2000; 35(1): 36-44. 6. Arteaga E, Araújo AQ, Bernstein M, Ramires Felix JA, Ianni BM, Fernandes F, et al. Valor prognóstico da fração de volume de colágeno na cardiomiopatia hipertrófica. Arq Bras Cardiol 2009;92(3): 222-6. 7. Chan RH,Maron BJ,Olivotto I, etal.Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation.2014; 130(6):484-95. 8. Maron MS, Maron BJ. Clinical impact of contemporary cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy. Circulation 2015;132(4):292-8. 9. Rowin EJ, Maron MS. The role of cardiac MRI in the diagnosis and risk stratification of hypertrophic cardiomyopathy. Arrhythmia & Electrophysiology Review 2016;5(3):197–202. 10. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 2012; 60(14):1249-56. 11. Madrigal-Matute J, Lindholt JS, Fernandez-Garcia CE, Benito-Martin A, Burillo E, Zalba G, et al. Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. J Am Heart Assoc. 2014; 3(4):pii:e000785. 12. Sharma UC, Pokharel S, Van Brakel TJ, Van Berlo JH, Cleutjens JP, Schroen B, et al. Galectin-3marks activatedmacrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110(19):3121-8. 13. De Boer RA, Daniels LB, Maisel AS, Januzzi JL Jr. State of the art: newer biomarkers in heart failure. Eur J Heart Fail. 2015;17(6):559-69. 14. De Boer RA, Yu L and van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep. 2010;7(1):1-8. 15. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012;60(14):1249-56. 16. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012; 110(1):159-73. 17. Filipe MD, Meijers WC, Rogier van der Velde A, de Boer RA . Galectin-3 and heart failure: prognosis, prediction & clinical utility. Clin ChimActa. 2015 Mar 30;443:48-5. 18. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101(25):2981-8. 19. Bohl S, Wassmuth R, Abdel-Aty H, Rudolph A, Messroghli D, Dietz R, et al. Delayed enhancement cardiac magnetic resonance imaging reveals typical patterns of myocardial injury in patients with various forms of nonischemic heart disease. Int J Cardiovasc Imaging. 2008;24(6):597-607. 20. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J AmColl Cardiol 2003;41(9):1561-7. 21. Lombardi R, Betocchi S, Losi MA, Tocchetti CG, Aversa M, Marianna M, et al. Myocardial Collagen Turnover in Hypertrophic Cardiomyopathy. Circulation. 2003;108(12):1455-60. References Antunes et al. Galectin-3, myocardial fibrosis and hypertrophic cardiomyopathy Int J Cardiovasc Sci. 2019;32(2)152-157 Original Article Acknowledgments Biomerrieux do Brasil, for kit donations. Author contributions Conception and design of the research: Antunes MO, Arteaga-Fernández E. Acquisition of data: Antunes MO, Arteaga-Fernández E, Buck PC, Moreira CHV. Analysis and interpretation of the data: Antunes MO, Arteaga- Fernández E, Fernandes F, Soffiatti CD, Sabino EC. Obtaining financing: Antunes MO, Soffiatti CD. Writing of the manuscript: Antunes MO, Soffiatti CD, Buck PC. Critical revision of themanuscript for intellectual content: AntunesMO, Arteaga-Fernández E, Fernandes F,MadyC. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding There were no external funding sources for this study. Study Association This study is not associated with any thesis or dissertation work. Ethics approval and consent to participate This study was approved by the Ethics Committee of the Faculdade de Medicina da Universidade de São Paulo under the protocol number 0665/9 . All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.